Aprea Therapeutics, Inc. Operating Cash Flow
Aprea Therapeutics, Inc. (APRE) reported Operating Cash Flow of -$6.04 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-12
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.28M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$2.76M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$2.96M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$3.17M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$12.89M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$13.56M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$12.18M.
- Aprea Therapeutics, Inc. net cash provided by (used in) operating activities for fiscal 2022 was -$25.01M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$3.28M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.04M 10-Q · filed 2026-08-12 | -$9.00M derived: sum of 3 quarters · filed 2026-08-12 | -$12.17M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2026-03-31 | -$2.76M 10-Q · filed 2026-05-13 | -$5.72M derived: sum of 2 quarters · filed 2026-05-13 | -$8.89M derived: sum of 3 quarters · filed 2026-05-13 | -$12.02M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-12-31 | -$2.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$6.13M derived: sum of 2 quarters · filed 2026-03-16 | -$9.26M derived: sum of 3 quarters · filed 2026-08-12 | -$12.89M 10-K · filed 2026-03-16 | ||
| 2025-09-30 | -$3.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.30M derived: sum of 2 quarters · filed 2026-08-12 | -$9.93M 10-Q · filed 2025-11-12 | -$13.44M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-06-30 | -$3.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | -$6.76M 10-Q · filed 2026-08-12 | -$10.27M derived: sum of 3 quarters · filed 2026-08-12 | -$12.74M derived: sum of 4 quarters · filed 2026-08-12 | ||
| 2025-03-31 | -$3.63M 10-Q · filed 2026-05-13 | -$7.14M derived: sum of 2 quarters · filed 2026-05-13 | -$9.61M derived: sum of 3 quarters · filed 2026-05-13 | -$13.25M derived: sum of 4 quarters · filed 2026-05-13 | ||
| 2024-12-31 | -$3.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$5.98M derived: sum of 2 quarters · filed 2026-03-16 | -$9.62M derived: sum of 3 quarters · filed 2026-03-16 | -$13.56M 10-K · filed 2026-03-16 | ||
| 2024-09-30 | -$2.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$6.11M derived: sum of 2 quarters · filed 2025-11-12 | -$10.05M 10-Q · filed 2025-11-12 | -$13.79M derived: sum of 4 quarters · filed 2025-11-12 | ||
| 2024-06-30 | -$3.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$7.58M 10-Q · filed 2025-08-12 | -$11.32M derived: sum of 3 quarters · filed 2025-08-12 | -$13.56M derived: sum of 4 quarters · filed 2025-08-12 | ||
| 2024-03-31 | -$3.94M 10-Q · filed 2025-05-14 | -$7.68M derived: sum of 2 quarters · filed 2025-05-14 | -$9.92M derived: sum of 3 quarters · filed 2025-05-14 | -$13.13M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | -$3.74M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | -$5.98M derived: sum of 2 quarters · filed 2025-03-25 | -$9.20M derived: sum of 3 quarters · filed 2025-03-25 | -$12.18M 10-K · filed 2025-03-25 | ||
| 2023-09-30 | -$2.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$5.46M derived: sum of 2 quarters · filed 2024-11-07 | -$8.44M 10-Q · filed 2024-11-07 | -$12.46M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-06-30 | -$3.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | -$6.20M 10-Q · filed 2024-08-12 | -$10.22M derived: sum of 3 quarters · filed 2024-08-12 | -$16.81M derived: sum of 4 quarters · filed 2024-08-12 | ||
| 2023-03-31 | -$2.98M 10-Q · filed 2024-05-14 | -$7.00M derived: sum of 2 quarters · filed 2024-05-14 | -$13.59M derived: sum of 3 quarters · filed 2024-05-14 | -$22.49M derived: sum of 4 quarters · filed 2024-05-14 | ||
| 2022-12-31 | -$4.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$10.61M derived: sum of 2 quarters · filed 2024-03-26 | -$19.52M derived: sum of 3 quarters · filed 2024-03-26 | -$25.01M 10-K · filed 2024-03-26 | ||
| 2022-09-30 | -$6.59M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$15.50M derived: sum of 2 quarters · filed 2023-11-09 | -$20.99M 10-Q · filed 2023-11-09 | -$31.17M derived: sum of 4 quarters · filed 2024-03-26 | ||
| 2022-06-30 | -$8.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$14.40M 10-Q · filed 2023-08-10 | -$24.58M derived: sum of 3 quarters · filed 2024-03-26 | -$32.81M derived: sum of 4 quarters · filed 2024-03-26 | ||
| 2022-03-31 | -$5.50M 10-Q · filed 2023-05-15 | -$15.67M derived: sum of 2 quarters · filed 2024-03-26 | -$23.91M derived: sum of 3 quarters · filed 2024-03-26 | -$31.66M derived: sum of 4 quarters · filed 2024-03-26 | ||
| 2021-12-31 | -$10.18M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | -$18.41M derived: sum of 2 quarters · filed 2024-03-26 | -$26.16M derived: sum of 3 quarters · filed 2024-03-26 | -$37.69M 10-K · filed 2024-03-26 | ||
| 2021-09-30 | -$8.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | -$15.99M derived: sum of 2 quarters · filed 2022-11-09 | -$27.51M 10-Q · filed 2022-11-09 | -$40.71M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2021-06-30 | -$7.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-12 | -$19.27M 10-Q · filed 2022-08-12 | -$19.27M 10-Q · filed 2021-08-12 | -$32.47M derived: sum of 3 quarters · filed 2023-03-30 | -$43.90M derived: sum of 4 quarters · filed 2023-03-30 | |
| 2021-03-31 | -$11.52M 10-Q · filed 2022-05-16 | -$24.72M derived: sum of 2 quarters · filed 2023-03-30 | -$36.14M derived: sum of 3 quarters · filed 2023-03-30 | -$45.78M derived: sum of 4 quarters · filed 2023-03-30 | ||
| 2020-12-31 | -$13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | -$24.62M derived: sum of 2 quarters · filed 2023-03-30 | -$34.26M derived: sum of 3 quarters · filed 2023-03-30 | -$41.80M 10-K · filed 2023-03-30 | ||
| 2020-09-30 | -$11.42M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-08 | -$21.06M derived: sum of 2 quarters · filed 2021-11-08 | -$28.60M 10-Q · filed 2021-11-08 | -$43.35M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2020-06-30 | -$9.64M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$17.18M 10-Q · filed 2021-08-12 | -$31.92M derived: sum of 3 quarters · filed 2022-03-15 | -$34.72M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2020-03-31 | -$7.54M 10-Q · filed 2021-05-06 | -$22.28M derived: sum of 2 quarters · filed 2022-03-15 | -$25.08M derived: sum of 3 quarters · filed 2022-03-15 | -$30.05M derived: sum of 4 quarters · filed 2022-03-15 | ||
| 2019-12-31 | -$14.74M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | -$17.54M derived: sum of 2 quarters · filed 2022-03-15 | -$22.51M derived: sum of 3 quarters · filed 2022-03-15 | -$26.71M 10-K · filed 2022-03-15 | ||
| 2019-09-30 | -$2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | -$7.77M derived: sum of 2 quarters · filed 2020-11-06 | -$11.97M 10-Q · filed 2020-11-06 | -$16.21M 10-Q · filed 2019-11-14 | -$15.82M derived: sum of 4 quarters · filed 2021-03-16 | |
| 2019-06-30 | -$4.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-11 | -$9.17M 10-Q · filed 2020-08-11 | -$13.02M derived: sum of 3 quarters · filed 2021-03-16 | |||
| 2019-03-31 | -$4.20M 10-Q · filed 2020-05-15 | -$8.05M derived: sum of 2 quarters · filed 2021-03-16 | ||||
| 2018-12-31 | -$3.85M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | -$15.25M 10-K · filed 2021-03-16 | ||||
| 2018-09-30 | -$11.40M 10-Q · filed 2019-11-14 | |||||
| 2017-12-31 | -$14.00M 10-K · filed 2020-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |